Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

I think that there is little difference between Everolimus, Ridaforolimus, and Temsirolimus.

Without head to head trials, this is just complete conjecture on your part. What we do know, however, is that comparable data is available in both sarcoma and endometrial trials and ridaforolimus outperformed everolimus in both efficacy and safety.
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34086
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52969

IMO, the only thing Ariad is getting out of dosing at higher levels in Ridaforolimus is harsher side effects including stomach lacerations and harsher ulcers in the mouth and intestinal tract.

This is simply more "opinion" on your part that just isn't supported by the facts. If anything the percentage and type of AE's have been associated more with mTors as a class than with the individual drugs. However, in the case of P2 endometrial trial, more than half of all pts who achieved CBR ultimately discontinued everolimus because of toxicity.